CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 12 enrolled
Drug / intervention
PF-06463922 +1 moredrug
Likely dose
PF-06463922 100 mg orally, single dose; rifampin 600 mg once dailyAI-extracted
Key inclusion· 4
  • ✓Age 18-55 years inclusive
  • ✓Healthy female subjects of non-childbearing potential and/or male subjects
  • ✓BMI 17.5 to 30.5 kg/m²
  • ✓Total body weight >50 kg (110 lbs)
Key exclusion· 6
  • ✕Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease
  • ✕Any condition possibly affecting drug absorption
  • ✕Positive urine drug screen
  • ✕History of HIV, Hepatitis B, or Hepatitis C

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02804399
NCT02804399Phase 1Completed
CompareCT.gov

A Phase One, Open Label, Two-period, Two-treatment, Fixed Sequence, Cross-over Study To Estimate The Effect Of Multiple Dose Rifampin On The Single Dose Pharmacokinetics Of Pf-06463922 In Healthy Volunteers.

Pfizer·interventional·Posted Jun 17, 2016·Updated Jan 25, 2019

In Brief

A Phase 1 clinical trial evaluating PF-06463922 and rifampin for Healthy. Completed, enrolled 12 participants across 1 site.

Detailed Summary

The purpose of this study is to estimate the effect of rifampin on the single dose PK of PF-06463922.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 17, 2016
Enrollment StartJul 1, 2016
Primary CompletionOct 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 10.0 years ago

Interventions

PF-06463922drug

100 mg oral dose on day 1 in period 1 and on day 8 in period 2

rifampindrug

600 mg QD from day 1 to day 12 in period 2.